Alcon (ALC) 43rd Annual J.P. Morgan Healthcare Conference 2025 summary

Strategic Focus and Innovation

• Emphasis on eye care specialization, leveraging expertise to drive capital investment in new markets and technologies.

• Global reach in 130 countries enables rapid product uptake and unique customer experiences.

• Continuous reinvestment in R&D, with ~$4 billion invested since the spin-off, focusing on global commercialization and operating leverage.

• Focus on resilient, durable markets with underlying 4% growth, aiming to outpace the market through innovation and acquisitions.

• Margin improvement targeted, with mid-20s margin goal by 2027 and significant free cash flow growth in 2024.

Product Pipeline and Launches

• Launch of PRECISION7, a seven-day contact lens, addresses a market gap between daily and monthly lenses.

• Systane Pro, a new triple-acting dry eye product, and AR-15512/512, a TRPM8 agonist for dry eye, expected to launch in the back half of the year or pending FDA approval.

• PanOptix Pro and Clareon platforms advance multifocal cataract surgery, reducing light scatter and improving image contrast, with US launch in 1H 2025.

• Unity platform integrates diagnostics and surgical planning, with new phaco-vit machine launching in April/May and UNITY VCS/CS system FDA-cleared for Q2 2025.

• Voyager DSLT for glaucoma leverages reimbursement codes, is FDA-cleared, and launching in the US in Q1 2025.

Operational Efficiency and Market Outlook

• Unity platform and new VCS equipment designed to improve surgical throughput and efficiency, reducing diagnostic and OR times.

• Consumables remain a core profitability driver, with new equipment expected to extend this for another decade.

• Contact lens market expected to grow 5-6%, with 2% from pricing, 3% from trade-up, and 1% from volume.

• Currency fluctuations present EPS pressure; spot rates will be used for future guidance.

• Capital allocation prioritizes organic investment, bolt-on M&A, and shareholder returns via dividends.